The purpose of the present study was to estimate the relative contributions of degradation and brain-to-blood elimination processes to the clearance of microinjected human amyloid-b peptide(1-40) (hAb(1-40)) from mouse cerebral cortex, using a solid-phase extraction method together with a newly developed ultraperformance liquid chromatography/tandem mass spectrometry (UPLC/MS/MS) quantitation method for intact hAb(1-40). The clearance rate constant of hAb(1-40) in mouse cerebral cortex was determined to be 3.21 Â 10 À 2 /min under conditions where the saturable brain-to-blood elimination process across the blood-brain barrier (BBB) was expected to be saturated. Thus, this clearance rate constant should mainly reflect degradation. The [ 125 I]hAb(1-40) elimination rate across the BBB under nonsaturating conditions was determined to be 1.48 Â 10 À 2 /min. Inhibition studies suggested that processes sensitive to insulin and phosphoramidon, which inhibit neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme, are involved not only in degradation, but also in elimination of hAb(1-40). In conclusion, our results suggest a dominant contribution of degradation to cerebral hAb(1-40) clearance, and also indicate that a sequential process of degradation and elimination of degradation products is involved in cerebral hAb(1-40) clearance.
INTRODUCTION
The accumulation of amyloid-b peptide (Ab) in extracellular space is thought to trigger Ab aggregation and deposition, which contribute to development of Alzheimer's disease (AD). 1, 2 Amyloid-b peptide is normally produced and cleared at the same rate in human brain. 3 In late-onset AD (99% of cases), the clearance rate of Ab from brain is lower than that in non-AD brains, but there is no significant difference in Ab production rate. 4 Thus, impaired clearance of soluble Ab could be the major cause of elevated levels of Ab, ultimately leading to deposition of Ab aggregates in the brain. 5 Cerebral clearance of soluble Ab involves both degradation in the brain [6] [7] [8] and brain-to-blood elimination across the blood-brain barrier (BBB). 9, 10 The relative contributions of these processes are poorly understood, though this information would be important to understand in detail the pathogenesis of AD, and also to develop treatments.
Therefore, the aim of the present study was to evaluate the degradation and brain-to-blood elimination rate constants of human Ab (hAb)(1-40) from mouse brain by using a newly developed ultraperformance liquid chromatography/tandem mass spectrometry (UPLC/MS/MS) method for quantitation of intact hAb(1-40) after microinjection of hAb , and thus to estimate separately the contributions of the two processes to cerebral Ab clearance in mouse. The elimination rate of hAb(1-40) from the rodent cerebral cortex has been determined from the time course of 125 I radioactivity remaining in the ipsilateral cerebrum. 10, 11 However, intact and degraded hAb(1-40) cannot be distinguished by measuring radioactivity. The degradation of Ab has also been examined by using labeled hAb or knockout mice. [6] [7] [8] [9] [10] However, to separate the contributions of degradation or elimination to cerebral clearance of hAb , it is necessary to quantify both the radiolabel and intact hAb .
For quantification of intact hAb , enzyme-linked immunosorbent assay has been widely used. However, enzyme-linked immunosorbent assay results can be influenced by crossreactivity of Ab antibody, the presence of Ab binding protein, and/or nonspecific binding of compounds in brain extract. 12 However, quantification by means of liquid chromatography/tandem mass spectrometry (LC/MS/MS) with selected/multiple reaction monitoring (SRM/MRM) has the advantages of high selectivity and reliability. 13 Therefore, for the present work we used a solidphase extraction (SPE) procedure to concentrate Ab from brain extract without anti-Ab antibody treatment, 14 followed by quantitation of intact hAb(1-40) with a newly developed UPLC/ MS/MS method. The combination of this approach with radioactivity measurements allowed us to estimate separately the contributions of degradation and elimination to cerebral Ab clearance in our experimental model.
MATERIALS AND METHODS Animals
Male C57BL/6J mice (8 to 10 weeks old) were purchased from Japan SLC (Hamamatsu, Japan). The protocol was approved by the Institutional Animal Care and Use Committee at Tohoku University (Sendai, Japan). The investigation using animals described in this report conformed to the guidelines of the Animal Care Committee, Graduate School of Pharmaceutical Sciences, Tohoku University.
Reagents
Human amyloid-b peptide in HFIP solution were determined by amino-acid sequence analysis as described previously. 15 Unlabeled hAb(1-40) peptide was dried and then dissolved in distilled water or 0.1% ammonium hydroxide containing 20% acetonitrile before use.
Mass Spectrometric Analysis of Unlabeled Human Amyloid-b Peptide(1-40) and [ 15 N]-Labeled Human Amyloid-b Peptide
Unlabeled hAb(1-40) and [ 15 N]hAb(1-40) were detected by following a specific m/z transition from a precursor peptide ion in Q1 to a product peptide ion in Q3 (SRM/MRM transition). A solution of hAb(1-40) in 0.1% ammonium hydroxide containing 20% acetonitrile (1 mmol/L) was injected into the MS/MS (API5000; Applied Biosystems, Foster City, CA, USA) at 5 mL/ min to optimize MS/MS SRM/MRM conditions in the negative ion mode ( Table 1 ).
Preparation of Standard Solutions
For preparing the calibration curves, unlabeled hAb(1-40) was diluted in 1.5 mL tubes with 200 mL of 0.1% ammonium hydroxide containing 20% acetonitrile by serial dilution of hAb(1-40) (0, 20, 40, 200, 400, 2,000, and 4,000 fmol) spiked into 1 pmol of [ 15 N]hAb(1-40) as an internal standard. Aliquots of 50 mL of these solutions (0, 5, 10, 50, 100, 500, and 1,000 fmol standard/250 fmol internal standard) were injected into the column.
Quantification of Human Amyloid-b Peptide(1-40) by Ultraperformance Liquid Chromatography/Tandem Mass Spectrometry
Human amyloid-b peptide(1-40) and [ 15 N]hAb were analyzed with a UPLC system (Waters ACQUITY UPLC system, Waters Co., Milford, MA, USA) connected to an ESI-triple quadrupole mass spectrometer (API5000; Applied Biosystems). hAb solution was injected into a reversedphase UPLC column (ACQUITY UPLC BEH C18 column 1.7 mm, 2.1 mm ID Â 50 mm, Waters) with the column oven set at 251C. Mobile phase A consisted of 0.1% ammonium hydroxide and mobile phase B consisted of 0.1% ammonium hydroxide containing 20% acetonitrile. The peptides were separated and eluted from the column using the following gradient system: 0 to 2 minutes 15% B, 2 to 7 minutes 15-30% B, 7.0 to 7.01 minutes 30-60% B, 7.01 to 9 minutes 60% B, 9.0 to 9.01 minutes 60 to 15% B, 9.01 to 14 minutes 15% B at a flow rate of 0.5 mL/min. Samples dissolved in 0.1% ammonium hydroxide containing 20% acetonitrile were added to the sample tray held at 41C, and 50 mL aliquots of the samples were injected into the column with an auto sampler. To prevent carry-over, 50 mL of 0.1% ammonium hydroxide containing 20% acetonitrile was injected between sample injections. The MS was set up to run an SRM/MRM experiment for detection of each hAb(1-40) ( Table 1 ). The ion counts in the chromatograms were determined by using the quantitation procedures in Analyst software version 1.4.2 (Applied Biosystems). Human amyloid-b peptide was quantified by calculating the ratios of peak areas to those of isotopelabeled peptides, as described previously. 15 Extraction of Human Amyloid-b Peptide(1-40) from Mouse Brain [ 15 N]hAb(1-40) (1 pmol) was spiked into samples as an internal standard just before homogenization. Mouse brains were homogenized in nine volumes of 6 mol/L guanidinium hydrochloride (GuHCl) solution in a tissue homogenizer (Model PT1300D; Kinematica AG, Littau, Switzerland) and incubated for 3 hours on ice. Samples were ultracentrifuged at 100,000 g for 60 minutes at 41C with a TLA-55 rotor using an Optima MAX-E ultracentrifuge (Beckman, Fullerton, CA, USA) and the supernatants were collected in new 1.5 mL tubes. Unlabeled hAb(1-40) and [ 15 N]hAb(1-40) were extracted from the supernatant of mouse brain homogenate by SPE as described previously, with minor modifications. 12 An Oasis HLB 1 mL (30 mg) extraction cartridge (Waters) was placed on a vacuum manifold and equilibrated using 1 mL of water followed by 1 mL of methanol. Samples were passed through the prepared SPE cartridges at 1 mL/min. To reduce sample loss, 200 mL of 6 M GuHCl solution was added to the sample tubes and these solutions were passed over the prepared SPE cartridges at 1 mL/min again. The SPE cartridges were then washed sequentially with 1 mL of 10% and 30% methanol, and then eluted with 1 mL of 2% NH 4 OH in 90% MeOH. Eluted samples were dried in a centrifuge concentrator (Tomy Seiko Co., Ltd., Tokyo, Japan). Once samples had been dried completely, they were stored at À 801C until assay. The dried samples were resuspended in 200 mL of 0.1% ammonium hydroxide containing 20% acetronitrile, and these samples (50 mL) were analyzed by UPLC/MS/MS as described above.
Recovery of hAb(1-40) from mouse brain homogenates was determined according to equation 1;
Recovery of hAbð1-40Þ ð%Þ ¼ 
Measurement of FITC-Inulin in Mouse Brain
The supernatants of mouse brain homogenate were 10-fold diluted with 500 mmol/L HEPES (pH 7.4), because pH significantly affects the fluorescence of FITC. 16 The duplicate samples were then loaded onto a 96-well plate (100 mL sample/well). The standard solution was diluted with mouse brain homogenate without microinjection of FITC-inulin. Fluorescence was determined using a Fluoroscan Ascent FL (FIN-00811; Labsystems, Helsinki, Finland) with excitation at 485 nm and emission at 538 nm. Recovery of inulin in the supernatant of mouse brain homogenate after microinjection was 96.5 ± 0.5% (n ¼ 4, data not shown), as determined by 14 C-radioactivity measurement of [ 14 C]inulin in the supernatant and pellet of brain homogenate.
Brain Efflux Index Method
The in vivo brain elimination experiments were performed using the intracerebral microinjection technique previously reported. 11 Briefly, mice were anesthetized with an intramuscular injection of xylazine (1.22 mg/kg) and ketamine (125 mg/kg), and placed in a stereotaxic frame (SRS-6; Narishige, Tokyo, Japan) that determines the coordinates of the mouse brain coinciding with the secondary somatosensory cortex (S2) region. After microinjection, the microsyringe was left in place for 4 minutes to minimize any backflow. At designated times after microinjection, the ipsilateral (left) and contralateral (right) cerebrum and cerebellum were excised. For measurement of intact hAb(1-40) and FITC-inulin by UPLC/MS/MS analysis and fluorescence spectrometry, the brain and applied solution (0.30 ml) were snap frozen in liquid nitrogen. The amounts of intact hAb(1-40) and FITCinulin in mouse brain were measured as described above. For measurement of 125 I and 3 H radioactivity, brains were dissolved in 2.0 mL 2 M NaOH at 601C for 1 hour. The 125 I and 3 H radioactivity of the samples were measured in a g-counter (ART300, Aloka, Tokyo, Japan) for 3 minutes and a liquid scintillation counter (TRI-CARB2050CA, Packard Instruments, Meriden, CT, USA) for 5 minutes, respectively. We previously showed that no significant radioactivity was found in the contralateral cerebrum, cerebellum, or CSF at 60 minutes after microinjection of [ 125 I]hAb(1-40), 11 indicating that [ 125 I]hAb(1-40) did not diffuse to these regions from the injected hemisphere. In that study, the amount of microinjected [ 3 H]dextran, a BBB-impermeable compound, was not significantly changed after microinjection, 11 indicating that the BBB remained intact during the Brain Efflux Index (BEI) study. The cerebral clearance was defined according to equation 2, and the percentage of intact hAb(1-40) remaining in the ipsilateral cerebrum was determined using equation 3:
Cerebral clearance ð%Þ ¼ Clearance of intact hAbð1-40Þ from the ipsilateral cerebrum Intact hAb ð1-40Þ injected into the brain
Percentage remaining in the ipsilateral cerebrum ð%Þ ¼ Amounof intact hAb ð1-40Þ in the brain=amount of FITCÀinulin in the brain Concentration of intact hAbð1-40Þ injected=concentration of FITCÀinulin injected
The clearance rate constant, reflecting both degradation in the brain and elimination across the BBB, was determined from the slope obtained by fitting a semilogarithmic plot of remaining percentage of intact hAb in the ipsilateral cerebrum versus time, using the nonlinear least-squares regression analysis program MULTI. 17 To characterize the clearance system in the brain, the clearance rate constant calculated from the slope of the profile of percentage remaining in the ipsilateral cerebrum at 5 and 30 minutes was determined in the presence or absence of several inhibitors.
The BEI was defined according to equation 4, and the percentage of substrate remaining in the ipsilateral cerebrum (100-BEI) was determined using The apparent brain-to-blood elimination rate constant across the BBB was determined from the slope obtained by fitting a semilogarithmic plot of (100-BEI) versus time, using the nonlinear least-squares regression analysis program MULTI. 17 To characterize the efflux transport system at the BBB, the elimination rate constant across the BBB calculated from the slope of the profile of (100-BEI (%)) at 5 and 30 minutes was determined in the presence or absence of several inhibitors.
Data Analysis
Unless otherwise indicated, all data represent the mean±s.e.m. One-way analysis of variance followed by Dunnett's test was used to assess the statistical significance of differences among the means of more than two groups.
RESULTS

Quantification of Human Amyloid-b Peptide(1-40) by Liquid
Chromatography/Tandem Mass Spectrometry with Selected/ Multiple Reaction monitoring Full scanning analyses were performed in the range of m/z 600 to 1,200 for hAb(1-40) and [ 15 N]hAb(1-40) and two product ions were selected for SRM/MRM analysis ( À 5 ion transition and À 4 ion transition). Mixtures of different amounts of hAb(1-40) (5, 10, 50, 100, 500, and 1,000 fmol) and 250 fmol of [ 15 N]hAb(1-40), used as an internal standard, were measured under optimal conditions using the two SRM/MRM transitions. Calibration curves showed linear regression lines in the range of 5 to 1,000 fmol for hAb(1-40) (R 2 ¼ 0.999 for the À 5 ion transition and 0.996 for the À 4 ion transition) ( Figure 1A ). There was no significant difference in peak area ratio determined using the two different SRM/MRM transitions (R 2 ¼ 0.999; Figure 1B ). The limit of detection of hAb(1-40) was 1.42 fmol for the À 5 ion transition and 3.24 fmol for the À 4 ion transition. To improve reliability, the amount of hAb(1-40) was determined from the values of both SRM/MRM transitions.
Before homogenizing brain tissue, a fixed amount of [ 15 N]hAb(1-40) was spiked into each sample as an internal standard, and loss of hAb(1-40) during sample preparation, including SPE, was compensated by determining the peak area ratio of hAb(1-40) to [ 15 N]hAb . Nevertheless, a low recovery of hAb(1-40) might still result in inaccuracy of quantification. Therefore, the recovery rate of hAb(1-40) was determined by comparing the amounts of [ 15 N]hAb(1-40) in two samples: one in which [ 15 N]hAb(1-40) was added before brain homogenization and one in which it was added after SPE. The recovery rate of [ 15 N]hAb(1-40) determined from 116 measurements (n ¼ 58 each for À 5 ion transition and À 4 ion transition) was 74.2±1.2%. This suggested that recovery of hAb(1-40) from mouse brain in the procedure with SPE was sufficient.
Detection of Human Amyloid-b Peptide in Mouse Brain After Microinjection Human amyloid-b peptide(1-40) (5 mmol/L) was microinjected into the S2 region of mouse brain, and the remaining amount was measured at 30 minutes after microinjection by means of UPLC/ MS/MS analysis. The peaks of hAb(1-40) and [ 15 N]hAb(1-40) were detected at same retention time using either the À 5 or À 4 ion transition (Figures 2A and 2B) . In contrast, no significant peak of Figures 2C and 2D ). There was a high peak at the retention time of 7.5 minutes in all measured samples in either the À 5 or À 4 ion transition, and this appears to be a nonspecific peak derived from the mouse brain. The peak area ratio of the À 5 ion to À 4 ion of [ 15 N]hAb(1-40) from brain (0.953; Figures 2A and 2B ) was decreased compared with that in the calibration curve sample (1.53; Figures 2E and 2F ). This is presumably due to a greater ion suppression effect of the more highly charged ion, although the ratio of hAb(1-40) to [ 15 N]hAb(1-40) was not different in the two cases.
Clearance of Intact Human Amyloid-b Peptide(1-40) from Mouse Brain Clearance of intact hAb(1-40) from mouse brain was investigated by quantifying intact hAb(1-40) remaining in the brain after microinjection. Figure 3 shows the time profile of the percentage of intact hAb(1-40) remaining in the ipsilateral cerebrum after microinjection of 5 mmol/L hAb(1-40) into the S2 region of mouse brain. Remaining intact hAb(1-40) decreased in a time-dependent manner, and the clearance rate constant was determined to be 3.21 Â 10 À 2 ±0.42 Â 10 À 2 /min (mean±s.d.).
Inhibitory Effect of Amyloid-b Peptide-Degrading Enzyme Inhibitors on Clearance of Intact Human Amyloid-b Peptide(1-40) in Mouse Brain
To investigate the contribution of degradation processes to hAb(1-40) clearance, the effects of various enzyme inhibitors on the clearance of intact hAb(1-40) in mouse brain were examined ( The inhibitory effects of the same inhibitors were examined on elimination of 125 I radioactivity from the mouse brain across the BBB after microinjection of [ 125 I]hAb(1-40). 125 I radioactivity was cleared from mouse brain with an elimination rate constant of 1.48 Â 10 À 2 ± 0.17 Â 10 À 2 /min (mean ± s.d., Table 3 ); this represents brain-to-blood elimination of intact and/or degraded [ 125 I]hAb(1-40) from the brain to blood across the BBB. Coadministration of a mixture of insulin (100 mg/mL) and phosphoramidon (10 mmol/L), thiorphan (1 mmol/L), and insulin (100 mg/mL) significantly inhibited the elimination of 125 I radioactivity and the elimination rate constants were decreased by 97.8%, 35.7%, and 41.4%, respectively (Table 3) .
DISCUSSION
In the present study, we developed a new quantitation method for intact hAb(1-40) in mouse brain by means of SPE followed by UPLC/MS/MS (Figures 1 and 2 ). Since hAb(1-40) is identified in terms of LC retention time and molecular mass, with stable isotope-labeled [ 15 N]hAb(1-40) as an internal standard, UPLC/MS/ MS quantification affords higher specificity than antibody-based quantification. Although the sensitivity of the present UPLC/MS/ MS quantification of hAb(1-40) is at least 10-fold lower than that of commercial enzyme-linked immunosorbent assay, the SPE step can concentrate hAb(1-40) from large volumes of biologic samples. Human amyloid-b peptide(1-42) was previously reported to be recovered by the same SPE method 12 and quantified by LC/MS/MS followed by immunoprecipitation. 13 Therefore, it seems likely that various derivatives of hAb can be quantified by UPLC/MS/MS with high specificity, provided that they can be recovered by SPE. Using the developed method, the clearance rate constant of intact hAb(1-40) (5 mmol/L) in mouse brain was determined to be 3.21 Â 10 À 2 /min ( Figure 3 ). The clearance of intact hAb(1-40) reflects both degradation by proteases and brain-to-blood elimination by efflux transport at the BBB. We previously reported that the Km value of [ 125 I]hAb(1-40) elimination across the rat BBB was 247 nmol/L (injectate concentration). 10 The elimination rate constant in rat was 1.42 Â 10 À 2 /min, and 28.5% of the elimination was estimated to be due to a nonsaturable (or low affinity) component. 10 A self-inhibition study showed that 20 mmol/L hAb(1-40) decreased the elimination rate constant across the BBB to 28.9%. 10 Similarly, in the mouse study, the elimination rate constant across the BBB was 1.48 Â 10 À 2 /min (Table 3) , and 20 mmol/L hAb(1-40) decreased the elimination rate constant to 37.5%. 11 Therefore, it appears that the Km value of [ 125 I]hAb(1-40) elimination across the BBB in mouse is similar to that in rat. If this is the case, then the concentration of microinjected hAb(1-40) (5 mmol/L) was 20.2-fold greater than the Km value. Therefore, we can assume that the saturable component of hAb(1-40) elimination from mouse brain across the BBB was saturated. Accordingly, the elimination rate constant across the BBB can be estimated to be 0.560 Â 10 À 2 /min when 5 mmol/L hAb(1-40) was microinjected, as shown in Table 2 (see Supplementary  Information for detailed calculations) .
The Km values of NEP, IDE, and endothelin-converting enzyme for hAb have been reported to be in the micromolar range, [18] [19] [20] being much greater than the estimated hAb(1-40) concentration in the injected area, and this suggests that the Ab degradation process was not saturated. Taking these findings into consideration, the clearance and elimination rate constants across the BBB determined in this study are summarized in Figure 4 . From the observation that Ab-degrading enzyme inhibitors inhibited [ 125 I]hAb(1-40) elimination across the BBB (Table 3 ) and our previous finding that both intact and degraded [ 125 I]hAb were detected in plasma at 5 minutes after microinjection into rat cerebral cortex, 10 two different brain-to-blood elimination pathways appear to operate; one is the elimination of intact hAb , and the other is the elimination of degradation products of hAb . The elimination rate constant of intact hAb(1-40) across the BBB was estimated to be less than 0.560 Â 10 À 2 /min from the UPLC/MS/MS study ( Figure 4A ). The degradation rate constant of intact hAb(1-40) was estimated to be at least 2.69 Â 10 À 2 /min (3.25 Â 10 À 2 -0.560 Â 10 À 2 /min), which is at least 1.8-fold greater than the apparent elimination rate constant of hAb(1-40) across the BBB (Figures 4A and 4B ). On the basis of these calculations, it appears that degradation has a dominant role in cerebral clearance of hAb .
The clearance of hAb(1-40) was almost completely inhibited by insulin and phosphoramidon ( Table 2) , indicating that hAb(1-40) was degraded mainly via insulin-or phosphoramidon-sensitive pathways, which include the reactions catalyzed by IDE, NEP, and endothelin-converting enzyme. The inhibitory effects of insulin alone and thiorphan alone suggest that insulin-and thiorphansensitive degradation processes account for at least 54.8% and 84.6% of hAb(1-40) degradation in the brain ( Table 2 ). It was reported that microinjection of thiorphan (1 mmol/L) and phosphoramidon (10 mmol/L) into rat hippocampus markedly inhibited degradation of radiolabeled hAb(1-42). 21 The Km value of insulin for IDE is 25 nmol/L, 22 which is B23-fold lower than the estimated insulin concentration at the injection site (568 nmol/L). Thus, these inhibitors appear to be present at sufficiently high concentrations to inhibit Ab degradation in the brain. The roles of NEP and IDE in Ab accumulation in mouse brain have been investigated using the corresponding gene-deficient mice. 7, 8 In NEP-deficient mouse brain, endogenous Ab(1-40) was increased by B2-fold compared with wild-type mice. 8 In IDE-deficient mouse brain, endogenous Ab(1-40) was increased by B1.2to 1.6-fold compared with wildtype mice. 7, 23 The greater effect of NEP is consistent with the contribution of each protease suggested by the present study (Table 2 ). Furthermore, when the percentage contributions of IDE and NEP to the degradation were added, the total was greater than 100%, suggesting that some part of intact hAb(1-40) is degraded by both IDE and NEP. The elimination of [ 125 I]hAb(1-40) from the brain across the BBB was inhibited by thiorphan (Table 3 ). Thiorphan (10 mmol/L) did not inhibit the internalization of [ 125 I]hAb(1-40) into conditionally immortalized mouse brain capillary endothelial cells (TM-BBB4). 24 This in vitro concentration was close to the estimated concentration of thiorphan at the injection site in vivo (33 mmol/ L ¼ 1 mmol/L/30.3), since injectate was reported to be diluted at least 30.3-fold by diffusion in the brain. 25 This result suggests that NEP-degraded [ 125 I]hAb(1-40) was partially eliminated from the brain by efflux transport at the BBB. The thiorphan-sensitive clearance rate constant was estimated to be 2.75 Â 10 À 2 /min (3.25 Â 10 À 2 (control) À 0.499 Â 10 À 2 /min ( þ thiorphan); Table 2 ), and the thiorphan-sensitive elimination rate constant across the BBB was estimated to be 0.53 Â 10 À 2 /min (1.48 Â 10 À 2 (control)-0.95 Â 10 À 2 /min ( þ thiorphan); Table 3 ). On the basis of these rate constants, B19% of the [ 125 I]hAb(1-40) degradation products . A mixture of hAb(1-40) (1.5 pmol) and FITC-inulin (9 mg) dissolved in 0.30 mL of ECF buffer was injected into the S2 region of mouse brain in the presence or absence of inhibitors. The clearance rate constant was calculated from the slope of the profile of (100-BEI (%)) at 5 and 30 minutes (each point n ¼ 3 to 4). Each value represents the mean ± s.d.. **Po0.01, ***Po0.001, significantly different from control. in the brain (yellow box), which includes the brain parenchyma and brain capillary endothelial cells (BCEC). The determined clearance rate constant represents both degradation of intact hAb(1-40) and brain-to-blood elimination of intact hAb(1-40) across the blood-brain barrier (BBB) (red arrows). The elimination rate constants of intact and degraded hAb(1-40) were estimated as described in Discussion and Supplementary Information. (B generated by NEP appears to be eliminated from the brain across the BBB on the assumption that thiorphan inhibited only the hAb(1-40) degradation process. Since the elimination study using [ 125 I]hAb(1-40) covered the elimination of only degraded peptides containing 125 I-labeled tyrosine, further study may be necessary to examine the elimination of degraded peptide(s) not containing labeled tyrosine and also to clarify the molecular mechanism of the elimination of hAb(1-40) from the brain across the BBB. Insulin also inhibited the elimination of [ 125 I]hAb(1-40) from the brain across the BBB. One possible explanation is that degradation products of [ 125 I]hAb(1-40) generated by IDE were partially eliminated from the brain by efflux transport at the BBB. However, insulin is also a ligand of various receptors, and the possibility that insulin inhibited the internalization of [ 125 I]hAb(1-40) into capillary endothelial cells cannot be excluded. Our previous report showed that low-density lipoprotein receptor-related protein 1 does not contribute to the elimination of [ 125 I]hAb(1-40) from mouse cerebral cortex, but unknown molecules, whose function may be insulin sensitive, have a role in the elimination. 10, 11 Indeed, [ 125 I]hAb(1-40) internalization into TM-BBB4 cells was inhibited by insulin (100 mg/mL), but not by thiorphan (10 mmol/L) or phosphoramidon (100 mmol/L), supporting the idea that an insulin-sensitive internalization process is involved in the elimination of Ab from the brain across the BBB. 24 The present study examined the clearance of hAb(1-40) in mouse brain. Neprilysin and IDE are expressed in human brain, and their activities are reduced age and region specifically. [26] [27] [28] Postmortem studies indicate that NEP protein expression and activity were inversely associated with AD pathology. [26] [27] [28] [29] [30] [31] [32] [33] Thus, it seems reasonable to assume that these proteins, especially NEP, are involved in Ab(1-40) clearance in human brain. As for the brain-to-blood elimination process, our in vitro study showed that [ 125 I]hAb(1-40) internalization into mouse brain capillary endothelial cell line (TM-BBB4) was significantly inhibited by unlabeled mouse Ab(1-40), 24 suggesting that hAb(1-40) and mouse Ab(1-40) share the same molecular mechanism of internalization into mouse brain capillary endothelial cells. The molecule responsible for hAb(1-40) elimination across the BBB remains unknown even in rodents. The available evidence suggests that cerebral hAb(1-40) clearance in humans involves similar molecular mechanisms to those in rodents, at least in part. Although the in vivo experiments performed in the present study could not be performed in humans, several human BBB models have recently become available, such as D3 cells, 34 TY08 cells, 35 and human brain capillary endothelial cells derived from induced pluripotent stem cells. 36 Further experiments using these human cells should help to establish the relevance of our mouse data to humans, as well as providing more details of the mechanisms of cerebral hAb(1-40) degradation and elimination in human brain.
In conclusion, our present study suggests that both degradation and elimination are involved in the cerebral clearance of hAb(1-40). Furthermore, an insulin-or thiorphan-sensitive process was involved in both degradation and elimination. A part of hAb(1-40) was eliminated from the brain across the BBB via successive processes of degradation and elimination of the degradation product(s). It remains important to clarify the molecular mechanisms of this multistep clearance system to understand the pathophysiologic role of hAb(1-40), and to identify potential therapeutic targets for AD.
